When Were Stem Cells Discovered? A Historical Timeline

The term “stem cell” first appeared in scientific writing in the late nineteenth century, but proving that such cells actually exist took another hundred years of painstaking work. What we now call “stem cell science” is not the product of a single eureka moment. It emerged in fits and starts across embryology, cancer biology, blood research, and genetics, with each generation of scientists building on concepts their predecessors could only theorize about. The story spans from German microscopy labs in the 1860s to twenty-first-century efforts to build synthetic embryo-like structures entirely from cultured cells.

The Term Before the Science

The German biologist Ernst Haeckel is generally credited with first using the word “Stammzelle,” literally “stem cell,” in the 1860s and 1870s. Haeckel used it in two overlapping ways: to describe the hypothetical single-celled ancestor of all multicellular life, and to describe the fertilized egg from which an individual organism develops.¹ His colleague August Weismann drew the first cellular “stem tree” diagram, visualizing how a single cell might branch into the many specialized types that make up a body.¹

By the turn of the twentieth century, the term had migrated into two distinct fields. Embryologists like Theodor Boveri used “stem cell” to describe cells that gave rise to the germline, the lineage that produces eggs and sperm. Meanwhile, hematologists including Ernst Neumann, Artur Pappenheim, and Alexander Maximow applied the same term to a proposed master cell in the bone marrow that could generate all blood cell types.² Boveri was particularly influential in describing two properties that still define stem cells today: the ability to copy themselves (self-renewal) and the ability to produce more specialized daughter cells (differentiation).³

These early ideas were purely conceptual. Nobody could isolate a stem cell or watch one produce different cell types under a microscope. The concept of a single undifferentiated cell sitting at the root of a branching developmental tree was powerful as a framework, but it would take most of the twentieth century to prove it was also real.

Proving Blood Stem Cells Exist

The first rigorous experimental evidence for stem cells came in 1961 from two Canadian researchers, James Till and Ernest McCulloch, working at the Ontario Cancer Institute in Toronto. They transplanted bone marrow cells into mice that had received lethal doses of radiation and then examined the animals’ spleens. Visible nodules formed on the spleens, and Till and McCulloch showed that each nodule was a colony derived from a single transplanted cell. Those single cells could both renew themselves and produce the full range of blood cell types.⁴

This spleen colony assay, known as the CFU-S assay, was the first functional test of “stemness” at the single-cell level. It established the two core criteria still used to define a stem cell: self-renewal and the capacity to differentiate into multiple mature cell types. The experiment also laid the groundwork for bone marrow transplantation as a medical therapy, which has since been performed close to 1.5 million times worldwide to treat blood cancers and other diseases.

Cancer Clues That Led to Embryonic Stem Cells

An unlikely path to understanding normal stem cells ran through cancer biology. In the 1950s and 1960s, researchers noticed that a particular inbred mouse strain, strain 129, was prone to developing testicular tumors called teratocarcinomas. These bizarre growths contained a chaotic mix of tissue types: teeth, hair, bone, muscle, and nerve tissue could all appear in a single tumor. The tumors grew from a specific subpopulation of malignant cells called embryonal carcinoma (EC) cells, which behaved like the stem cells of the tumor, endlessly self-renewing and spawning the varied tissues found within it.⁵

The key insight was that EC cells resembled the pluripotent cells of the early embryo. If a cancerous cell could produce every tissue type, perhaps the normal cells of the very early embryo could do the same, and more controllably. Researchers eventually showed that the malignancy arose because normal embryonic stem cells had essentially gone rogue, proliferating without the usual developmental brakes.⁶ This line of thinking traced a direct path from tumor biology to the later isolation of embryonic stem cells from healthy embryos.⁷

Mouse Embryonic Stem Cells in 1981

The teratocarcinoma work set the stage for one of the landmark achievements in stem cell biology. In 1981, Martin Evans and Matthew Kaufman in Cambridge, along with Gail Martin at the University of California, San Francisco, independently reported that they had isolated pluripotent cell lines directly from mouse embryos at the blastocyst stage. Evans and Kaufman showed that these cells had normal chromosomes and could differentiate into multiple tissue types both in culture and when injected into mice.⁸

These were the first true embryonic stem (ES) cells: not cancerous, not transformed, just normal pluripotent cells grown indefinitely in a lab dish. The mouse ES cell lines became an indispensable tool for genetics research, because scientists could modify specific genes in these cells and then use them to create genetically altered mice. Evans shared the 2007 Nobel Prize in Physiology or Medicine for this work.

The Stem Cell Niche

While experimentalists were learning to grow stem cells in dishes, a quieter conceptual revolution was also underway. In 1978, Ray Schofield proposed what became known as the stem cell “niche” hypothesis. He argued that stem cells do not maintain themselves in isolation; they depend on signals from the surrounding tissue environment, or microenvironment, to stay in a stem-like state. Without the right niche, a stem cell loses its defining properties.⁹

Schofield went further, suggesting that “stemness” is not a fixed identity locked inside one special cell type. Instead, he proposed that a range of cells in a tissue possess stem cell potential to varying degrees, and that the niche determines which ones actually function as stem cells at any given time. This was a radical departure from the idea of the stem cell as a single, rare, intrinsically special cell. The niche concept has since become central to understanding how stem cells behave in tissues from the gut lining to the brain.

Dolly and Nuclear Reprogramming

In 1996, Ian Wilmut and Keith Campbell at the Roslin Institute in Scotland announced the birth of Dolly the sheep, the first mammal cloned from an adult cell. The technique, somatic cell nuclear transfer (SCNT), involved removing the nucleus from an adult mammary gland cell and placing it into an egg cell whose own nucleus had been removed. The egg then reprogrammed the adult nucleus back to an embryonic state, and the resulting embryo developed into a live lamb.¹⁰

Dolly’s significance for stem cell science went beyond the cloning headline. She proved that an adult cell’s DNA still contains all the information needed to build an entire organism, and that something in the egg cytoplasm can reset an adult nucleus to a state resembling early development. As one retrospective put it, the greatest legacy of the Dolly experiment was making biologists think differently: if unknown factors in the egg could reprogram a nucleus, there had to be other ways to achieve the same change.¹⁰ That prediction came true within a decade.

Human Embryonic Stem Cells in 1998

James Thomson at the University of Wisconsin-Madison reported the first human embryonic stem cell (hESC) lines on November 6, 1998, publishing in the journal Science. Thomson derived five cell lines, designated H1, H7, H9, H13, and H14, from donated human blastocysts.¹¹ The cells had normal chromosomes, high telomerase activity (suggesting they could divide for a long time without aging), and the ability to produce cell types from all three embryonic germ layers: gut tissue, bone, muscle, cartilage, nerve tissue, and skin, among others.¹²

The announcement triggered both enormous scientific excitement and immediate ethical and political controversy, because deriving hESCs requires the destruction of a human embryo. Debates over federal funding restrictions, particularly in the United States, dominated stem cell policy discussions for the next decade and shaped the direction of research in ways that accelerated the search for alternative sources of pluripotent cells.

Cancer Stem Cells

Running parallel to the embryonic stem cell story was a growing realization that cancers themselves harbor small populations of cells with stem-like properties. The idea that tumors might be sustained by a minority of self-renewing cells had been floating around for decades, but the first definitive experimental evidence came in 1997, when John Dick and Dominique Bonnet at the University of Toronto showed that human acute myeloid leukemia is organized as a hierarchy originating from a rare cell with the self-renewal and differentiation capacity of a stem cell.¹³ Later studies described similar cancer stem cells in solid tumors of the breast and brain, raising the possibility that stem-cell-driven hierarchies exist across many cancer types.¹⁴

The cancer stem cell concept has practical consequences: if a treatment kills most tumor cells but spares the stem-like ones, the cancer can regrow. This realization has redirected some drug development efforts toward targeting the self-renewal pathways specific to these cells.

Induced Pluripotent Stem Cells

In 2006, Shinya Yamanaka and Kazutoshi Takahashi at Kyoto University announced a finding that reshaped stem cell biology. By introducing just four genes into ordinary mouse skin cells, they reprogrammed those cells into a pluripotent state closely resembling embryonic stem cells. They named these induced pluripotent stem (iPS) cells.¹⁵ The following year, Yamanaka’s group showed the same four factors could reprogram adult human skin cells into human iPS cells that were nearly indistinguishable from human embryonic stem cells in their gene expression, growth properties, and ability to produce all three germ layers.¹⁶

The discovery fulfilled the prediction inspired by Dolly: reprogramming did not require an egg cell. A handful of transcription factors could do it. Yamanaka shared the 2012 Nobel Prize in Physiology or Medicine with John Gurdon, who had performed the pioneering nuclear transfer experiments in frogs decades earlier. iPS cells largely sidestepped the embryo-destruction controversy that had dogged hESC research, and they opened the door to creating patient-specific pluripotent cells for disease modeling and potential therapies.

Overturning Old Dogmas About Adult Stem Cells

For most of the twentieth century, neuroscience held firmly to the belief that the adult brain could not produce new neurons. Santiago Ramón y Cajal, the Nobel Prize-winning father of modern neuroscience, had famously declared that in the adult nervous system, “the nerve paths are something fixed and immutable. Everything may die, nothing may be regenerated.” In the 1960s, however, researchers began finding evidence that new neurons do form in certain regions of the adult brain, overturning Cajal’s dogma and revealing neural stem cells as the source.¹⁷

Similar surprises emerged in the gut. In 2009, Hans Clevers and colleagues identified Lgr5 as a marker for cycling stem cells at the base of intestinal crypts. They demonstrated that a single Lgr5-positive stem cell, removed from the intestine and placed in the right growth conditions, could self-organize into a three-dimensional “mini-gut” or organoid that contained all the differentiated cell types of the intestinal lining.¹⁸ The same marker and culture approach was then extended to stomach tissue.¹⁹ Organoid technology has since become a widely used research tool, allowing scientists to grow miniature versions of the liver, kidney, brain, and other organs in a dish.

From Lab to Clinic

Translating stem cell discoveries into treatments has been slower and harder than early optimism suggested. Bone marrow transplantation, based on the hematopoietic stem cell work from the 1960s, was the first stem cell therapy to become a standard clinical treatment and remains the most established one. The first clinical trial using cells derived from human embryonic stem cells, run by the biotech company Geron, enrolled its first spinal cord injury patient in October 2010 but stopped the trial just one year later for business reasons unrelated to safety.²⁰

Since then, clinical trials using both embryonic stem cells and iPS cells have expanded, focusing on conditions where functional adult stem cell types are hard to access or grow. Eye diseases, Parkinson’s disease, spinal cord injuries, and type 1 diabetes have emerged as leading candidates for pluripotent stem cell-based therapies.²¹ Progress is real but incremental, and the field has learned hard lessons about the gap between a powerful laboratory tool and a safe, effective treatment.

Transdifferentiation and Direct Reprogramming

Yamanaka’s work showed that cells could be pushed backward in developmental time, from a specialized state to a pluripotent one. But other researchers have shown that cells can also be pushed sideways, converted directly from one specialized type to another without passing through a pluripotent stage. This process, called transdifferentiation or direct lineage reprogramming, was demonstrated both in culture and inside living animals.²²

Direct reprogramming has obvious therapeutic appeal: if you need heart muscle cells, why not convert nearby cells in the heart itself, skipping the steps of first creating pluripotent cells, growing them, coaxing them into heart cells, and then transplanting them? The approach is still early-stage, but it challenges the old textbook view that differentiation is a one-way street. It also blurs the boundary between “stem cell therapy” and “cell conversion therapy,” since no stem cell may be involved at all.

Single-Cell Technologies and the Modern View

One reason stem cell biology was so hard to sort out historically is that stem cells are rare and mixed in with many other cell types. A scoop of bone marrow or a sliver of brain tissue contains thousands of different cells at different stages of maturity, and traditional techniques could only measure averages across the whole population. Single-cell RNA sequencing, which became practical in the 2010s, changed this dramatically. By reading the gene activity of individual cells one at a time, researchers can now map the full spectrum of cell states in a tissue and trace the paths individual stem cells take as they mature.²³ Studies using this approach on human pluripotent stem cells have already identified differentiation pathways into neural, muscle, liver, and other lineages, revealing branching decisions at a resolution earlier generations of researchers could not have imagined.²⁴

Synthetic Embryos and the Newest Frontier

The most recent chapter in stem cell history involves building embryo-like structures entirely from stem cells, with no egg or sperm involved. Researchers have created mouse “blastoids,” structures that closely resemble natural blastocysts, by combining different types of stem cells in tiny non-adherent wells and supplying them with the right cocktail of signaling molecules. The cells self-organize into layered structures that mirror the architecture of a real embryo.²⁵

These synthetic embryo models are being developed as tools for studying early human development and testing drugs without using actual human embryos. They also raise fresh ethical questions about how far a lab-built structure should be allowed to develop, and whether the existing rules written for embryo research apply to something that was never fertilized. The technology is advancing rapidly and has been called a revolutionary avenue for understanding how embryos form and how tissues organize themselves.²⁶

Plant Stem Cells and a Broader Perspective

Most discussions of stem cell history focus on animals, but plants have their own stem cell systems that were recognized in parallel. The growing tips of roots and shoots, called meristems, contain undifferentiated cells that continuously produce new tissue throughout the plant’s life. Unlike most animals, plants grow indefinitely, and their stem cells remain active for centuries in long-lived species like bristlecone pines and redwoods.²⁷

Plant stem cells have found commercial applications in the cosmetics industry, where extracts from apple and grape meristems are marketed as anti-aging ingredients. The scientific basis for these claims is thin compared to the rigor of medical stem cell research, but the products reflect how deeply the concept of stem cells has penetrated popular culture. Meanwhile, in biotechnology, plant stem cell cultures are being explored for producing valuable compounds like antioxidants and pharmaceuticals without needing to harvest whole plants. The history of stem cells, in other words, extends well beyond human medicine and continues to branch into unexpected territory.